Dysregulation of the P53 and B‐cell receptor signaling pathways was present in MYD88‐mutated DLBCL, which resulted in constitutive activation of nuclear factor kappa‐B (NF‐κB) pathway, resistance to chemotherapy, but sensitivity to the BTK inhibitor.41, 42, 43. Here, MYD88 is linked to diffuse large B-cell lymphoma.